In 118 post-MI patients with frequent PVCs, varenicline cut 24-hour PVC burden by 60.1 percentage points more than placebo over 6 weeks. Responders 67.8% vs 30.5%; non-sustained VT 20.3% vs 37.3%; adverse events comparable. Phase 2 trial.
RCTn = 118
Shen et al. Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study